<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527942</url>
  </required_header>
  <id_info>
    <org_study_id>12-01-003</org_study_id>
    <nct_id>NCT01527942</nct_id>
  </id_info>
  <brief_title>Intravenous Acetaminophen Use With Bariatric Surgery on Morbidly Obese Patients</brief_title>
  <official_title>Effect of Intravenous Acetaminophen on Postoperative Pain of Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Randomized, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Francis Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Francis Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric patients usually require the use of either intravenous or oral opioid medications.
      The use of opioids, however, is often associated with side-effects such as nausea, sedation
      pruritus, urinary retention and respiratory depression with often delay patient discharge.
      This study makes use of intravenous acetaminophen , a non-opioid analgesic preoperatively to
      determine if this will decrease the use of opioids post-operatively for pain management in
      morbidly obese patients undergoing laparoscopic bariatric surgery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study Terminated per Principal Investigator's request
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Relief Score on the 5-point Pain Relief Score Between Baseline and 24 Hours</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>The 5-point Pain Relief Score is self-reported and scores range from 0=none, 1=little, 2=some, 3=a lot, 4=complete. Change = (24 hour score - baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity on the 10-point Pain Intensity Scale Between Baseline and 24 Hours</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>The 10-point Pain Intensity Scale is self-reported and scores range from 0=no pain to10=worst possible. Change = (24 hour score - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate - of 3=Excellent at Hour 24 Using 4-point Global Satisfaction With Regards to Overall Pain Management Rating Scale 0=Poor to 3= Excellent.</measure>
    <time_frame>24 hours after baseline</time_frame>
    <description>The 4-point patient global satisfaction of pain management scale is self-reported and scores range from 0=poor to 3=excellent. Response rate of 3=excellent at 24 hours after baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Obesity</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Active Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Intravenous Acetaminophen 1,000 mg IV</description>
    <arm_group_label>Arm 1 - Active Drug</arm_group_label>
    <other_name>OFIRMEV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)</description>
    <arm_group_label>Arm 2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morbidly Obese and body mass index (BMI) of 35

          -  Between ages 20-17

          -  Candidates for Laparoscopic Bariatric Surgery

        Exclusion Criteria:

          -  know hypersensitivity to acetaminophen or opioids

          -  impairment in liver function

          -  renal dysfunction

          -  mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Raftopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>November 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2015</results_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain Management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 - Active Drug</title>
          <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 - Placebo</title>
          <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 - Active Drug</title>
          <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 - Placebo</title>
          <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20 to 70 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Relief Score on the 5-point Pain Relief Score Between Baseline and 24 Hours</title>
        <description>The 5-point Pain Relief Score is self-reported and scores range from 0=none, 1=little, 2=some, 3=a lot, 4=complete. Change = (24 hour score - baseline)</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Active Drug</title>
            <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Placebo</title>
            <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Relief Score on the 5-point Pain Relief Score Between Baseline and 24 Hours</title>
          <description>The 5-point Pain Relief Score is self-reported and scores range from 0=none, 1=little, 2=some, 3=a lot, 4=complete. Change = (24 hour score - baseline)</description>
          <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Intensity on the 10-point Pain Intensity Scale Between Baseline and 24 Hours</title>
        <description>The 10-point Pain Intensity Scale is self-reported and scores range from 0=no pain to10=worst possible. Change = (24 hour score - baseline)</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Active Drug</title>
            <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Placebo</title>
            <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Intensity on the 10-point Pain Intensity Scale Between Baseline and 24 Hours</title>
          <description>The 10-point Pain Intensity Scale is self-reported and scores range from 0=no pain to10=worst possible. Change = (24 hour score - baseline)</description>
          <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate - of 3=Excellent at Hour 24 Using 4-point Global Satisfaction With Regards to Overall Pain Management Rating Scale 0=Poor to 3= Excellent.</title>
        <description>The 4-point patient global satisfaction of pain management scale is self-reported and scores range from 0=poor to 3=excellent. Response rate of 3=excellent at 24 hours after baseline.</description>
        <time_frame>24 hours after baseline</time_frame>
        <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Active Drug</title>
            <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Placebo</title>
            <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate - of 3=Excellent at Hour 24 Using 4-point Global Satisfaction With Regards to Overall Pain Management Rating Scale 0=Poor to 3= Excellent.</title>
          <description>The 4-point patient global satisfaction of pain management scale is self-reported and scores range from 0=poor to 3=excellent. Response rate of 3=excellent at 24 hours after baseline.</description>
          <population>Study was terminated - data were determined to be unusable by IRB due to consent issues.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 24 hours after patients received either active drug or placebo</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - Active Drug</title>
          <description>Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Acetaminophen: Intravenous Acetaminophen 1,000 mg IV</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - Placebo</title>
          <description>Preoperative IV Placebo (0.9 NaCl 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
Placebo: Placebo - IV administration 0.9% 100 ml NaCl</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Investigator determined death not related to study drug; cause of death cardiomyopathy; death occurred (4 days) outside of reporting window as defined by study protocol</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ioannis Raftopoulos, MD</name_or_title>
      <organization>ST. FRANCIS HOSPITAL AND MEDICAL CENTER</organization>
      <email>IRaftopo@stfranciscare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

